Related Articles
Anti-CCL22 increases regulatory T cells in CD4+ T cells of rheumatoid arthritis patients via STAT5 pathway
Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer
Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide
CCL11 increases the proportion of CD4+CD25+Foxp3+ Treg cells and the production of IL‑2 and TGF‑β by CD4+ T cells via the STAT5 signaling pathway
Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells